Introduction: A number of prothrombotic and fibrinolytic disorders may lead to venous thrombosis. A 4G/5G polymorphism located in the promoter region of plasminogen activator inhibitor-1 (PAI-1) gene has been found to be commonly associated with the levels of PAI-1 and might be a risk factor for deep vein thrombosis (DVT). The aim of this study was to look for the potential association of this polymorphism with DVT in the Asian Indian population. Material and methods: A total of 110 consecutive patients (M:F ¼ 62:48) with idiopathic DVT and equal number of age-and sexmatched healthy controls were the study participants. All study participants were typed for the PAI-1 4G/ 5G polymorphism, factor V Leiden, factor V Hong Kong/Cambridge mutations, and HR2 haplotype. Result: The variant allele for the PAI-1 4G/5G polymorphism showed both genotypic (P ¼ .0013, 2 ¼ 10.303; odds ratio [OR] ¼ 3.75) as well as allelic association (P ¼ .0004, 2 ¼ 12.273; OR ¼ 1.99) with DVT. Factor V Leiden and factor V HR2 haplotype were observed in 10 (9.0%) and 13 (11.8%) patients, respectively. None of the study participants showed the factor V Hong Kong Cambridge mutations. Conclusion: Our study shows the association of 4G allele with DVT in Asian Indian population. The higher prevalence of 4G polymorphism in patients with DVT (compared with controls) seen in our study is in concordance with previous reports from the Caucasian population.
Introduction
A number of prothrombotic and fibrinolytic disorders may lead to venous thrombosis. One of the most common genetic disorders for deep vein thrombosis (DVT) is factor V Leiden (FVL). HR2 haplotype mutation has also been seen in activated protein C resistant patients. 1 Factor V Hong Kong/Cambridge mutations are also found in different Asian and Caucasian populations, but such mutations have not been noticed in Indian population till date. 1 Fibrinolytic system also plays a major role in hemostasis. An impaired fibrinolytic system may lead to DVT and the impairments occur due to mainly 2 reasons: (a) low concentration of tissue plasminogen activator (tPA) or (b) increased concentration of its inhibitor, plasminogen activator inhibitor-1 (PAI-1), in plasma. PAI-1, a specific plasminogen activator inhibitor, is a 55-kd glycoprotein synthesized by endothelial cells, hepatocytes, and megakaryocytes. 2 The human PAI-1 gene is located on chromosome 7 (q 21.3-q 22) and contains 8 introns and 9 exons. 3 Raised levels of PAI-1 in plasma may lead to a hypoactive fibrinolytic pathway creating conditions that might lead to DVT. Several polymorphisms in the PAI-1 gene have been found to correlate with plasma level of PAI-1 antigen and activity. A 4G/5G polymorphism characterized by a single guanosine insertion/deletion variation (5G or 4G) in the promoter region, situated 675 base pairs (bp) upstream from the transcriptional start site has been commonly found to be associated with the levels of PAI-1. Eriksson et al 4 demonstrated that 4G and 5G alleles bind a transcriptional activator (factor A), whereas 5G allele also binds a repressor protein (factor B) to an overlapping binding site, which decreases the binding of the activator by interference due to steric hindrance. Therefore, they suggested that the 4G allele may influence the level of PAI-1 transcription. In addition to this genetic polymorphism, raised plasma levels of PAI-1 are related to some anthropometric and metabolic factors of which plasma levels of triglycerides and insulin seem to be the most important. 5 In this study, we have looked at the risk posed by 4G/5G polymorphism of PAI-1 gene. There are no reports on the prevalence of this polymorphism in Indian patients with DVT.
Material and Methods
A total of 110 consecutive patients (M:F ¼ 62:48) with idiopathic DVT, confirmed by Doppler ultrasonography, computerized tomography (CT) scan (for cerebral venous thrombosis), presenting to the Department of Hematology for investigation were the participants of this study. There were 11 patients with metabolic syndrome in which 8 were diabetic and 3 were hypertriglyceridemic. Patients with pulmonary embolism were excluded from the study. The age of study participants ranged from 3 to 61 years. Most cases (82) were of lower limb thrombosis, whereas 15 cases were of upper limb thrombosis. Thrombosis at unusual sites was present in 13 cases, and these included cerebral (3), abdominal (6), subclavian (2), renal (1), and retinal vein (1). Informed consent was obtained from all individuals after obtaining approval by the local ethics committee. Blood samples were collected 3 months after the episode of thrombosis in siliconized glass containers, containing 3.2% sodium citrate solution. A total of 110 age-and sexmatched healthy controls with no past history of thrombosis were genotyped to determine the risk posed by the mutations. Genomic DNA was extracted from peripheral blood leucocytes by using standard methods. Genotyping of FVL, factor V Hong Kong/Cambridge and HR2 haplotype was done by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). 1 Genotypic screening protocols for 4G/5G were done through allele-specific PCR. Amplification of genomic DNA was done using the allele-specific primers, insertion 5G allele: 5 0 -GTC TGG ACA CGT GGG GG-3 0 , deletion 4G allele: 5 0 -GTC TGG ACA CGT GGG GA-3 0 each in a separate PCR reaction together with the common downstream primer 5 0 -TGC AGC CAG CCA CGT GAT TGT CTA G-3 0 and a control upstream primer 5 0 -AAG CTT TTA CCA TGG TAA CCC CTG GT-3 0 . The control upstream primer is used to verify the occurrence of DNA amplification in the absence of the allele on the genomic DNA. 6, 7 The gel for 4G/5G polymorphism is shown in Figure 1 .
Results
Factor V Leiden was seen in 10 of the 110 patients (9.0%). Of the 10 patients, 2 (1.81%) were homozygous for the mutant type and the rest, that is, 8 (7.27%) were heterozygous. None of the healthy controls was found positive for FVL. Factor V HR2 haplotype was seen in 13 of the 110 patients (11.8%) and 11 of the 110 controls (10%). All factor V HR2 haplotype carrying controls were heterozygous for the polymorphism. Of the 13 patients carrying the factor V HR2 haplotype, 1 (0.9%) was homozygous for the mutant type and the rest 12 were heterozygous ( Table 1) . Genotyping for 5G/4G polymorphism showed a prevalence rate of 48 (44%) and 29 (26%) for the 4G/4G genotype in patients and control population, respectively, which is significantly different (P ¼ .0013, 2 ¼ 10.303; odds ratio [OR] ¼ 3.75). The allelic frequency of 4G allele was 150 (68%) and 114 (52%) in patients and control population, respectively, which is also significantly different (P ¼ .0004, 2 ¼ 12.273; OR ¼ 1.99; Table 2 ). These results show that 4G allele is highly significantly associated with DVT patients.
Discussion
Defective fibrinolysis may play a role in the development of arterial and venous thrombosis. 8 A hypofibrinolysis due to raised PAI-1 levels was often observed in patients with hypertriglyceridemia, diabetes mellitus, arterial hypertension, overweight, and insulin resistance syndrome. 5 A study on metabolic syndrome by Naran et al 9 demonstrated that metabolic syndrome-related factors had little influence on PAI-1 level in white participants but had a major influence in Indian and African participants. Plasma PAI-1 concentration was found significantly higher in Indian and white participants than African participants because the frequency of 4G allele was low in African than in white and Indian participants. The PAI-1 4G/5G polymorphism was not associated with this disorder. We have also not found any specific pattern of this polymorphism in our patients with metabolic disorders of diabetes and hypertriglyceridemia. Impaired fibrinolysis due to increased PAI-1 might have a role in the pathogenesis of vascular diseases possibly by contributing to a prothrombotic state. 10 Several studies have shown the significant role of PAI-1 and its related hypofibrinolytic state in the development of myocardial infarction in patients with coronary artery disease and angina pectoris. 11 A study on stroke found that higher concentration of tPA/PAI-1 complex in plasma, a novel fibrinolytic marker, is independently associated with the development of ischemic stroke. 12 A PAI-1 promoter 4G/5G polymorphism has also been found associated with raised level of PAI-1 in different cohort studies. 3, 13 The PAI-1 promoter 4G/5G genotype was first detected at the À675 bp in the PAI-1 gene sequence, and its molecular defect was described by Eriksson et al 4 after that several studies have explained its clinical or biological significance. A number of studies have examined this 4G/5G genotype as a possible risk factor for thrombosis in different clinical groups or its contribution to circulating PAI-1 levels in several conditions, including healthy participant and patients with diabetes mellitus, DVT, and coronary diseases. 4, 11, 14 Two prospective nested casecontrol studies found that the 4G allele of the PAI-1 4G/5G promoter polymorphism was associated with an increased risk of future ischemic stroke. 15 Some of the published studies have revealed no relation between the PAI-1 promoter 4G/5G genotype and DVT. 16, 17 A study by Pegoraro et al 18 also found no such association between the PAI-1 promoter 4G/5G genotype and DVT in a study of young Asian Indians with acute myocardial infarction, but other studies have revealed such an association. 13 Hence, there have been contraindicatory reports on the role of 4G/5G polymorphism in raising the level of PAI-1 in patients with DVT from different populations. There are also some metabolic factors (eg, triglycerides, insulin, etc) that play an important role in regulating the level of PAI-1 in plasma. Thus, further studies will be necessary to determine the genetic and metabolic factors responsible for alterations in baseline fibrinolytic potential. 5, 19 Our study has shown an association of the 4G allele with DVT in Asian Indian population ( Figure 2 ) The higher prevalence of 4G polymorphism in our patients with DVT (compared with controls) supports the earlier reports from the Caucasian population that the 4G allele is significantly associated with DVT. 13 In a previous study, a significant higher prevalence of impaired fibrinolytic capacity due to PAI-1 excess was found in those patients with DVT who were carriers of the 4G allele. 3 The genotypic and allelic frequencies of 4G polymorphism are found significantly associated with DVT ( Table 1) . We found a significant reduction in the prevalence of 5G/5G genotype in patients with DVT as compared with healthy participants. Several studies have also found an association of the 4G polymorphism with the increase in PAI-1 antigen level. In fact the highest PAI-1 levels were found in 4G homozygous patients, intermediate levels in 4G/5G patients, and the lowest levels found in 5G homozygous patients. 14 Segui et al 20 not only showed the association between genotype and plasma levels of PAI-1 in patients with DVT but also demonstrated that the 4G allele is a determinant of PAI-1 concentration irrespective of the metabolic parameters and may significantly increase the risk of thrombosis in patients with inherited prothrombotic defects. An important variable that could be investigated alongside PAI in future studies is thrombin activatable fibrinolysis inhibitor (TAFI). TAFI is an important fibrinolytic inhibitor, which is gaining importance from the researchers' standpoint because of its tight genetic control. This inhibitor assumes more importance for researchers who work on the Fibrinolytic pathway. As far as the condition of venous thrombosis goes, initial reports suggested only a mild influence of the TAFI polymorphisms on DVT 21 ; however, recent reports do suggest that the relationship maybe more complex than it was previously made out to be. 22 In light of these reports, it would be interesting to study some of these polymorphisms (-438 G/A, 505 A/G, and 1040 C/T), which might have functional relevance in the background of PAI variants. Unfortunately we have not done it in our study.
We can conclude from our results that the polymorphism 4G/5G may have an important role in the development of DVT. However, this needs to be replicated and confirmed in a larger multicentric population, which will account for the genetic heterogeneity of the Indian population. Moreover, simultaneous analysis of PAI-1 levels will also make genotype phenotype correlations clearer. 
